Diabetes mellitus is a chronic metabolic disorder affecting an estimated 422 million people worldwide, with men comprising a significant portion of that population. While the well-documented complications of diabetes—including neuropathy, nephropathy, and cardiovascular disease—dominate clinical discussions, the impact on male reproductive health often receives less attention. However, mounting evidence indicates that diabetes can profoundly impair sperm quality and fertility, making it a critical yet underappreciated factor in male infertility. This article explores the mechanisms through which diabetes compromises sperm function, the consequences for fertility outcomes, and evidence-based strategies for mitigating these effects. Understanding the full scope of diabetes on male reproduction is essential not only for achieving pregnancy but also for optimizing the health of future children, as paternal metabolic health can influence offspring development through both genetic and epigenetic pathways.

How Diabetes Affects Sperm Quality

The association between diabetes and diminished sperm quality is well established in the scientific literature. Men with type 1 and type 2 diabetes consistently exhibit alterations in standard semen parameters, including reduced sperm concentration, decreased total sperm count, diminished progressive motility, and higher proportions of morphologically abnormal sperm. These changes are not uniform across all men, but the trend is clear: poorly controlled diabetes correlates with poorer semen quality. The extent of impairment often mirrors the duration of the disease and the level of glycemic control, making diabetes severity a key determinant of reproductive risk. A 2019 systematic review and meta-analysis published in Human Reproduction Update confirmed that diabetic men have significantly lower sperm concentration and total motile sperm count compared to healthy controls, with effect sizes that are clinically meaningful for fertility prognosis.

Oxidative Stress and Sperm Damage

Oxidative stress is the dominant molecular mechanism linking hyperglycemia to sperm dysfunction. Chronically elevated blood glucose levels lead to an overproduction of reactive oxygen species (ROS) through several pathways, including glucose auto-oxidation, protein glycation, and mitochondrial dysfunction. Under normal conditions, seminal plasma contains antioxidants that neutralize ROS and protect spermatozoa. In diabetic men, however, the balance shifts toward pro-oxidation. Excess ROS attack polyunsaturated fatty acids in the sperm membrane, causing lipid peroxidation and loss of membrane integrity. This damage impairs motility and reduces the sperm's ability to fertilize an oocyte. Moreover, ROS can directly damage sperm DNA, leading to strand breaks, base modifications, and chromatin cross-linking. Such DNA fragmentation correlates with poor embryo development, higher miscarriage rates, and lower success in assisted reproductive technologies. The measurement of seminal ROS levels and total antioxidant capacity has been proposed as a clinical tool to assess oxidative stress in diabetic men, but standardized cutoffs are still evolving.

Hormonal Changes and Fertility

Diabetes disrupts the hypothalamic-pituitary-gonadal (HPG) axis, leading to hormonal imbalances that further compromise spermatogenesis. Low testosterone (hypogonadism) is common in men with both type 1 and type 2 diabetes. The mechanisms include insulin resistance at the testicular Leydig cells, reduced gonadotropin secretion due to altered GnRH pulsatility, and increased conversion of testosterone to estradiol via elevated aromatase activity in adipose tissue. Lower testosterone reduces libido and erectile function, but also directly impairs the differentiation of spermatogonia into mature sperm. Additionally, elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are often seen as compensatory responses to testicular damage, yet they can indicate primary testicular failure. Altered levels of sex hormone-binding globulin (SHBG) further complicate the picture, reducing bioavailable testosterone. A study of over 500 diabetic men found that serum testosterone was inversely correlated with HbA1c, suggesting that better glucose control may partially restore Leydig cell function. Clinicians should include morning total testosterone, SHBG, LH, and FSH in the routine workup of diabetic men with fertility concerns.

Epigenetic Modifications in Sperm

Emerging research suggests that diabetes can induce epigenetic changes in sperm, including altered DNA methylation patterns and histone modifications. These changes may affect the expression of genes critical for early embryonic development. For instance, hyperglycemia has been shown to modify methylation of imprinted genes such as IGF2 and H19 in sperm, which could influence fetal growth and metabolic programming. This epigenetic inheritance means that paternal diabetes may contribute to the health of offspring even when maternal glucose control is normal—a concept that underscores the importance of preconception health in men. Animal models demonstrate that paternal hyperglycemia leads to increased body weight and impaired glucose tolerance in offspring, and these effects persist across multiple generations. In human studies, children of fathers with type 1 diabetes have been reported to have higher risk of developing metabolic syndrome themselves. Although more research is needed to fully map the sperm epigenome in diabetic men, these findings elevate the clinical urgency of addressing paternal metabolic health before conception.

Sperm DNA Fragmentation

Beyond general oxidative damage, sperm DNA fragmentation (SDF) is a specific end point of diabetes-related genotoxicity. SDF measures the percentage of sperm with broken DNA strands. Normal levels are typically below 15–30% depending on the assay, but diabetic men often present with SDF indices above 30%. High SDF is associated with decreased fertilization rates, compromised embryo quality, and higher rates of spontaneous abortion. Even when fertilization occurs, embryos derived from high-SDF sperm have a higher incidence of aneuploidy and poorer implantation rates in IVF cycles. The strong association between glycated hemoglobin (HbA1c) and SDF suggests that tight glycemic control may reduce DNA damage, though recovery can take several months due to the duration of the spermatogenic cycle (approximately 74 days). Clinicians should consider SDF testing in diabetic men with otherwise normal semen parameters but unexplained infertility or recurrent pregnancy loss. A recent meta-analysis reported that the mean SDF difference between diabetic and non-diabetic men was over 10 percentage points, making it one of the most consistent biomarkers of reproductive damage.

Impact on Fertility

The cumulative effect of poorer sperm parameters, hormonal dysfunction, and DNA damage translates into reduced fertility potential. Men with diabetes take longer to achieve pregnancy with their partners compared to non-diabetic men, and they are more likely to require medical assistance to conceive. Studies report that the odds of infertility in diabetic men are roughly 1.5 to 2 times higher than in the general male population, even after controlling for age and BMI. Additionally, the severity of diabetes—as measured by duration, HbA1c levels, and presence of complications—correlates with worse fertility outcomes. In a large Danish cohort study, men with type 1 diabetes had a 30% increased risk of receiving a diagnosis of male factor infertility compared to men without diabetes, and the risk was higher in those with longer disease duration or microvascular complications.

Clinical Studies and Evidence

Large cohort studies have provided consistent data. A 2022 meta-analysis of 19 studies involving over 1,500 diabetic men found significant reductions in sperm concentration (mean difference −9.5 million/mL), total motility (−8.7%), and normal morphology (−3.1%) compared to controls. Another study focusing on men with type 1 diabetes noted that the duration of disease was inversely correlated with sperm count, suggesting a cumulative toxic effect. Japanese researchers reported that men with HbA1c >7.0% had a 2.7-fold increased risk of abnormal semen analysis compared to those with HbA1c ≤6.5%. Regarding fertility treatment outcomes, data from assisted reproduction clinics indicate that couples where the male partner has diabetes have lower clinical pregnancy rates per IVF cycle (approximately 30% vs. 38% in non-diabetic controls) and more cycles are needed to achieve live birth. Importantly, a 2021 study from the Society for Assisted Reproductive Technology found that even after adjusting for female age and embryo quality, male diabetes independently reduced live birth rates by about 15% in fresh IVF cycles. These findings reinforce the need for preconception optimization of glycemic control in men.

Combination with Other Metabolic Disorders

Diabetes rarely exists in isolation. Many diabetic men also have obesity, metabolic syndrome, or other components of insulin resistance. Each of these conditions independently harms sperm quality, creating a synergistic negative effect. Adipose tissue produces inflammatory cytokines (e.g., TNF-α, IL-6) that exacerbate oxidative stress, and obesity itself is associated with hormonal disturbances such as hyperestrogenism and reduced SHBG. Therefore, the metabolic milieu of a man with type 2 diabetes is particularly hostile to spermatogenesis. Addressing obesity alongside diabetes is critical for fertility improvement. A 2020 randomized trial comparing lifestyle intervention plus metformin versus metformin alone in obese diabetic men found that the lifestyle group achieved greater improvement in total motile sperm count after 6 months. Weight loss of 5–10% can lower HbA1c by 0.5–1.0 percentage points and reduces scrotal temperature by decreasing abdominal fat mass, which further protects sperm production.

Vascular and Neurological Complications

Chronic hyperglycemia damages blood vessels and nerves throughout the body, including those supplying the reproductive system. Erectile dysfunction (ED) is three to five times more common in diabetic men, often emerging earlier and with greater severity. Microvascular disease reduces blood flow to the corpora cavernosa, impairing erectile rigidity. Diabetic neuropathy can also affect the autonomic nerves that control ejaculation, leading to retrograde ejaculation (semen entering the bladder) or delayed ejaculation. Both conditions can directly reduce the ability to achieve pregnancy through intercourse, even if sperm quality is preserved. Retrograde ejaculation is particularly problematic because it markedly reduces ejaculate volume and can be misdiagnosed as oligospermia. These complications further underscore the need for comprehensive diabetes management to maintain sexual and reproductive function. Diagnostic workup should include a detailed sexual history, post-ejaculatory urinalysis for sperm if retrograde ejaculation is suspected, and assessment of peripheral neuropathy. First-line treatments for ED in diabetic men often include phosphodiesterase-5 inhibitors (e.g., sildenafil), but addressing underlying glycemic and vascular health remains foundational.

Increased Risk of Reproductive Tract Infections

Diabetes predisposes men to genitourinary infections, including epididymitis, prostatitis, and urethritis. Hyperglycemia impairs neutrophil function and humoral immunity, reducing the body's ability to clear pathogens. Chronic infections of the accessory glands can cause obstruction, inflammation, and seminal plasma abnormalities that harm sperm function. Additionally, repeated antibiotic use and the inflammatory microenvironment can further damage the seminiferous epithelium. Prevention and prompt treatment of infections are therefore essential components of fertility management in diabetic men. Practicing good hygiene, staying hydrated, and maintaining glycemic control are key preventive measures. When infections occur, culture-guided antibiotics should be used to minimize disruption of the seminal microbiome, which is known to influence sperm quality. Interestingly, recent studies suggest that certain probiotics may help restore the seminal flora after antibiotic therapy, though this remains an area of active investigation.

Management and Natural Interventions

Fortunately, many of the deleterious effects of diabetes on sperm quality are at least partially reversible. The cornerstone of management is optimal blood glucose control, supported by targeted nutritional and lifestyle interventions, and sometimes medical or surgical treatments. The spermatogenic cycle lasts about 74 days, so improvements in semen parameters may not be evident for at least 3 months after initiating therapy. This lag time should be communicated to patients to set realistic expectations and sustained motivation for behavior change.

Blood Glucose Control

Maintaining HbA1c below 6.5–7.0% (depending on individual risk factors) is associated with better semen parameters and reduced DNA fragmentation. Intensive insulin therapy in type 1 diabetes has been shown to improve sperm motility and morphology within 3–6 months of improved control. For type 2 diabetes, oral medications such as metformin may offer direct benefits beyond glucose lowering. Metformin reduces oxidative stress and may improve sperm quality independently, though some studies show mixed results. It is important to work with an endocrinologist to optimize glycemic control without causing severe hypoglycemia. Continuous glucose monitoring (CGM) can provide real-time feedback and help patients avoid both hyper- and hypoglycemic excursions, which are both detrimental to sperm quality. In a small pilot study, the use of CGM along with insulin pump therapy in type 1 diabetic men led to improvements in sperm motility that correlated with time-in-range metrics.

Antioxidant Supplementation

Given the central role of oxidative stress, antioxidant supplementation is a logical adjunct. A combination of vitamin C (500–1000 mg/day), vitamin E (400–800 IU/day), selenium (200 μg/day), coenzyme Q10 (200–300 mg/day), and L-carnitine (1–2 g/day) has shown promise in improving sperm parameters in diabetic men. However, the evidence base is modest, and not all studies show consistent benefit. Antioxidants should be used in physiologically moderate doses; excessive supplementation can paradoxically worsen oxidative balance. A simple approach is to encourage a diet rich in fruits, vegetables, nuts, and whole grains, which naturally provide a wide array of antioxidants. Some clinicians recommend a tailored antioxidant blend based on baseline seminal ROS and total antioxidant capacity measurements. In particular, coenzyme Q10 has shown promising results in improving sperm motility in diabetic men, possibly due to its role in mitochondrial electron transport and cellular energy production.

Lifestyle Modifications

Weight loss, regular exercise, and a Mediterranean-style diet improve insulin sensitivity, reduce oxidative stress, and lower HbA1c. Even a 5–10% reduction in body weight can yield significant improvements in semen quality. Physical activity enhances blood flow, reduces inflammatory markers, and may boost testosterone. However, excessive cycling (especially prolonged sitting on a bike seat) should be avoided as it may cause perineal pressure and testicular temperature elevation. Smoking cessation and limiting alcohol are also critical—both are pro-oxidant and exacerbate diabetic complications. A 2022 prospective study found that a structured exercise program consisting of 30 minutes of moderate-intensity activity five times per week improved both HbA1c and total motile sperm count in men with type 2 diabetes. Furthermore, stress reduction techniques, such as mindfulness and adequate sleep, are underappreciated but important factors, as chronic hyperglycemia activates the hypothalamic-pituitary-adrenal axis, which can further suppress reproductive hormones.

Medical Treatments for Diabetes and Fertility

When lifestyle and oral agents are insufficient, other glucose-lowering therapies must be considered. Newer agents such as GLP-1 receptor agonists (e.g., liraglutide, semaglutide) promote weight loss and improve metabolic health, potentially benefiting fertility, though direct data on sperm quality are limited. SGLT2 inhibitors appear neutral or possibly positive. In men with hypogonadism confirmed on morning serum total testosterone, testosterone replacement therapy (TRT) can improve libido and energy, but it suppresses endogenous spermatogenesis and can actually worsen fertility. Therefore, TRT should be avoided in men actively trying to conceive. Instead, clomiphene citrate or human chorionic gonadotropin (hCG) may be used to stimulate endogenous testosterone production while preserving sperm production. Consultation with a reproductive urologist or endocrinologist is essential. In some cases, treating underlying conditions such as sleep apnea can also improve testosterone levels and fertility outcomes, as sleep apnea is more common in diabetic men and independently associated with hypogonadism.

Fertility Treatments for Diabetic Men

If natural conception remains elusive, assisted reproductive technologies (ART) offer options. Intracytoplasmic sperm injection (ICSI) bypasses many of the functional defects caused by diabetes by directly injecting a single sperm into the oocyte. It is especially effective when sperm motility or morphology is poor. For men with azoospermia due to diabetic neuropathy or testicular failure, surgical sperm retrieval (micro-TESE) combined with ICSI can be successful. However, it is important to note that high SDF may still impair embryo development after ICSI; in such cases, the use of testicular sperm (which often has lower DNA fragmentation than ejaculated sperm) may improve outcomes. Before proceeding with ART, couples should undergo comprehensive evaluation, including a spermiogram, SDF testing, and hormonal profile. Controlled ovarian hyperstimulation in the female partner is usually unaffected by male diabetes, but the cycle timing should be coordinated with the male partner's treatment plan. A systematic review of ART outcomes in diabetic men reported that while pregnancy rates per cycle are lower, live birth rates with ICSI are comparable to historical controls when using testicular sperm for cases with very high SDF. This underscores the importance of tailored ART strategies.

Conclusion

Diabetes imposes a multifaceted burden on male fertility through oxidative stress, hormonal disruption, epigenetic alterations, DNA fragmentation, and complications such as ED and infections. The prevalence of diabetes among reproductive-age men is rising, making it an increasingly relevant cause of subfertility. Importantly, many of these effects are modifiable. Aggressive glycemic control, weight management, antioxidant-rich diets, and targeted medical therapy can restore or preserve sperm quality and improve the chances of conception. For men who continue to face infertility, ART—particularly ICSI—remains a viable pathway to fatherhood. Clinicians should routinely assess diabetes status and metabolic health in men presenting with infertility and incorporate reproductive goals into diabetes management plans. By addressing male diabetes proactively, we can not only improve fertility outcomes but also promote the long-term health of both fathers and their children. Future research should focus on defining optimal glycemic targets for male fertility, understanding the epigenetic legacy of paternal diabetes, and developing sperm-specific therapies that reduce oxidative damage during spermatogenesis.